Rare Presentation of Hypoglycemia in a Patient with Anaplastic Large-Cell Lymphoma
Anaplastic large-cell lymphoma is a rare type of aggressive non-Hodgkin’s lymphoma, and arriving at a final diagnosis for this tumor is a challenge for the healthcare providers. Usually, it involves the lymph nodes and extranodal tissues such as the lungs, skin, and other soft tissues. Its presentat...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-01-01
|
| Series: | Case Reports in Endocrinology |
| Online Access: | http://dx.doi.org/10.1155/2021/6843103 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832565644953911296 |
|---|---|
| author | Raed Aldahash |
| author_facet | Raed Aldahash |
| author_sort | Raed Aldahash |
| collection | DOAJ |
| description | Anaplastic large-cell lymphoma is a rare type of aggressive non-Hodgkin’s lymphoma, and arriving at a final diagnosis for this tumor is a challenge for the healthcare providers. Usually, it involves the lymph nodes and extranodal tissues such as the lungs, skin, and other soft tissues. Its presentation by extending into different organs such as the liver, lungs, bones, spleen, and thyroid is rare. Thus, involvement of other organs is very rare as we found in a 54-year-old male patient, a known case of hypertension and end-stage renal disease who was on hemodialysis, who presented to the emergency department with a history of generalized weakness and weight loss of about 20 kg for two months. The tumor cells are positive for CD45, CD30, CD15, MUMi, and Ki-67 (80%) and negative for CD20, PAX-5, CD79a, CD3, CD5, CD10, BCL6, BCL2, EMA, ALK-1, and CD138. The patient was hypoglycemic and hypercalcemic and was managed accordingly. The patient was evaluated, and the third assessment showed that hypoglycemia was resolved due to dexamethasone. The patient’s glucose storage was depleted most likely due to liver involvement plus poor general condition. It was asserted that the patient’s hypoglycemia could be related to his underlying malignancy. Also, the patient was advised to start tablet diazoxide 45 mg three times a day (3 mg/kg/day TID) in addition to levothyroxine tablet 50 mcg once a day. Tablet diazoxide was stopped, and nutritional support was recommended. This case reveals a rare systematic ALK-1-negative anaplastic large-cell lymphoma that involves multiple organs. The main learning point from this report is that these tumors can present atypically even in adults and can be ALK-1 negative, which is contrary to the typical systematic anaplastic large-cell lymphomas that are positive for ALK. |
| format | Article |
| id | doaj-art-4b1871106eca457083761c404b39878d |
| institution | Kabale University |
| issn | 2090-651X |
| language | English |
| publishDate | 2021-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Endocrinology |
| spelling | doaj-art-4b1871106eca457083761c404b39878d2025-02-03T01:07:06ZengWileyCase Reports in Endocrinology2090-651X2021-01-01202110.1155/2021/6843103Rare Presentation of Hypoglycemia in a Patient with Anaplastic Large-Cell LymphomaRaed Aldahash0Department of MedicineAnaplastic large-cell lymphoma is a rare type of aggressive non-Hodgkin’s lymphoma, and arriving at a final diagnosis for this tumor is a challenge for the healthcare providers. Usually, it involves the lymph nodes and extranodal tissues such as the lungs, skin, and other soft tissues. Its presentation by extending into different organs such as the liver, lungs, bones, spleen, and thyroid is rare. Thus, involvement of other organs is very rare as we found in a 54-year-old male patient, a known case of hypertension and end-stage renal disease who was on hemodialysis, who presented to the emergency department with a history of generalized weakness and weight loss of about 20 kg for two months. The tumor cells are positive for CD45, CD30, CD15, MUMi, and Ki-67 (80%) and negative for CD20, PAX-5, CD79a, CD3, CD5, CD10, BCL6, BCL2, EMA, ALK-1, and CD138. The patient was hypoglycemic and hypercalcemic and was managed accordingly. The patient was evaluated, and the third assessment showed that hypoglycemia was resolved due to dexamethasone. The patient’s glucose storage was depleted most likely due to liver involvement plus poor general condition. It was asserted that the patient’s hypoglycemia could be related to his underlying malignancy. Also, the patient was advised to start tablet diazoxide 45 mg three times a day (3 mg/kg/day TID) in addition to levothyroxine tablet 50 mcg once a day. Tablet diazoxide was stopped, and nutritional support was recommended. This case reveals a rare systematic ALK-1-negative anaplastic large-cell lymphoma that involves multiple organs. The main learning point from this report is that these tumors can present atypically even in adults and can be ALK-1 negative, which is contrary to the typical systematic anaplastic large-cell lymphomas that are positive for ALK.http://dx.doi.org/10.1155/2021/6843103 |
| spellingShingle | Raed Aldahash Rare Presentation of Hypoglycemia in a Patient with Anaplastic Large-Cell Lymphoma Case Reports in Endocrinology |
| title | Rare Presentation of Hypoglycemia in a Patient with Anaplastic Large-Cell Lymphoma |
| title_full | Rare Presentation of Hypoglycemia in a Patient with Anaplastic Large-Cell Lymphoma |
| title_fullStr | Rare Presentation of Hypoglycemia in a Patient with Anaplastic Large-Cell Lymphoma |
| title_full_unstemmed | Rare Presentation of Hypoglycemia in a Patient with Anaplastic Large-Cell Lymphoma |
| title_short | Rare Presentation of Hypoglycemia in a Patient with Anaplastic Large-Cell Lymphoma |
| title_sort | rare presentation of hypoglycemia in a patient with anaplastic large cell lymphoma |
| url | http://dx.doi.org/10.1155/2021/6843103 |
| work_keys_str_mv | AT raedaldahash rarepresentationofhypoglycemiainapatientwithanaplasticlargecelllymphoma |